A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT06255977

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06255977
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06255977. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-24 (actual); primary completion 2024-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage
Condition
Intracerebral Hemorrhage
Intervention (Drug)
CN-105
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
SDM Bio Service Inc. (class: not stated)

Record details

Record id
cardio:ct-nct06255977
Content hash
4d25f2ecfb3258d0ab7702d42fefa6dc43ae03dd2c0e198b47549462c4cded3b